Table 2.
Prevalence of Commonly Reported Comorbidities Among Adolescent and Young Adult Survivors by Time Since Diagnosis and Sex
| All AYAs (n = 271) | ≤1 Year since Dx (n = 141) | >1–5 Years since Dx (n = 70) | >5 Years since Dx (n = 60) | Women (n = 200) | Men (n = 71) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | n | % | |
| Depression | 75 | 28% | 37 | 26% | 23 | 33% | 15 | 25% | 57 | 29% | 18 | 25% |
| Anxiety | 74 | 27% | 35 | 25% | 20 | 29% | 19 | 32% | 62 | 31% | 12 | 17% |
| Asthma | 46 | 17% | 23 | 16% | 12 | 17% | 11 | 18% | 35 | 18% | 11 | 15% |
| High cholesterol | 41 | 15% | 15 | 11% | 11 | 16% | 15 | 25% | 35 | 18% | 6 | 8% |
| Hypertension | 40 | 15% | 13 | 9% | 10 | 14% | 17 | 28% | 35 | 18% | 5 | 7% |
| Arthritis | 28 | 10% | 12 | 9% | 5 | 7% | 11 | 18% | 23 | 12% | 5 | 7% |
| Diabetes | 26 | 10% | 8 | 6% | 8 | 11% | 10 | 17% | 23 | 12% | 3 | 4% |
| ≥1 comorbidity | 163 | 60% | 83 | 59% | 37 | 53% | 43 | 72% | 130 | 65% | 33 | 46% |
| Average number of comorbidities (out of 7) | 2 | Range 1–6 | — | — | — | — | — | — | — | — | — | — |
| ≥1 comorbidity requiring medication managementa | 102 | 38% | 46 | 33% | 22 | 31% | 34 | 57% | 84 | 42% | 18 | 25% |
| Average number of medications (out of 7) | 1.6 | Range 1–4 | — | — | — | — | — | — | — | — | — | — |
| ≥1 activity-limiting comorbidityb | 48 | 18% | 21 | 15% | 13 | 19% | 14 | 23% | 37 | 19% | 11 | 15% |
| Average number of limiting comorbidities (out of 7) | 1.5 | Range 1–5 | — | — | — | — | — | — | — | — | — | — |
a
Assessed by asking participants “Currently are you taking any prescription medication for condition XX?” for each comorbidity examined.
b
Assessed by asking participants “Is you activity limited by condition XX?” for each comorbidity examined.